Abstract

Background: The breast epithelial cells in patients with triple-negative breast cancer (TNBC) actually have specific estrogen receptor (ER) expression, and the abnormal glycosylation of UGT1A1 in TNBC cells resulted in abnormal expression and function of ERα through regulating the modification of ERα. Therefore, our study targets the role of UGT1A1 expression, then glycosylation modification of ERα (estrogen receptor α) and estrogen resistance in development of TNBC.Methods: The differential expression of mRNA and miRNA in TNBC tissues was tested. Luciferase activity was analyzed in TNBC cells treated with miR-452. Moreover, the human mammary gland and TNBC cell lines were dealt with estrogen and miR-452 or its inhibitors, then proliferation ability was further determined. Moreover, the role of interaction between UGT1A1 and ERα in the glycosylation modification of ERα and UGT activity, and metabolism of estrogen were assessed. The effects of miR-452 on TNBC by improving abnormal glycosylation modification of ERα by targeting UGT1A1 and estrogen resistance were studied in vitro and in vivo.Results: The expression level of UGT1A1 in TNBC tumor tissues was higher than its matched para-tumorous tissues, but the miR-452 expression was opposite. The glycosylation modification site of ERα expressed in TNBC cells was different from that of normal mammary epithelial cells. The estrogen 17β-estradiol (E2) significantly promoted mitotic entry of TNBC cells. The interaction between UGT1A1 and ERα affected the expression level of each other, as well as the UGT enzyme activity and proliferation of TNBC cells. UGT1A1 induced production of intracellular estrogens and TNBC proliferation, but it could be reversed by overexpression of ERα. Upregulation of ERα caused the downregulation of UGT1A1 and marked decrease of intracellular estrogen products, and then suppressed TNBC proliferation. Moreover, UGT1A1 was the target gene of miR-452; miR-452 antagomir restrained TNBC xenograft.Conclusion: Our results demonstrated that estrogen was a positive factor in the proliferation of TNBC cells at onset of mitosis through accentuating the expression and enzyme activity of UGT1A1. However, miR-452 targeted to UGT1A1, then regulated glycosylation modification of ERα, estrogen metabolism, and TNBC development associated with estrogen resistance.

Highlights

  • Breast cancer (BC) is the woman’s malignant tumor with the highest incidence and the second highest mortality rate in the world [1]

  • To verify the aforementioned hypothesis, this project aimed to explore the pivotal mechanism of the occurrence and development of triple-negative breast cancer (TNBC) by targeting estrogen metabolism and estrogen resistance associated with ERα expression and its abnormal glycosylation in TNBC

  • Our results indicated 21 differential mRNAs, including three downregulated mRNAs and 18 upregulated mRNAs in TNBC tumor tissues (Table 2). It indicated overexpression of UGT1A1 in TNBC tumor tissues compared with paratumor tissues

Read more

Summary

Introduction

Breast cancer (BC) is the woman’s malignant tumor with the highest incidence and the second highest mortality rate in the world [1]. The most dangerous type in BC is TNBC (triple-negative breast cancer). It is highly invasive, easy to metastasize, and has a poor prognosis [2]. Because the exact etiology and pathogenesis of TNBC is unknown, new targeted drugs have not achieved satisfactory clinical results [3]. The breast epithelial cells in patients with triple-negative breast cancer (TNBC) have specific estrogen receptor (ER) expression, and the abnormal glycosylation of UGT1A1 in TNBC cells resulted in abnormal expression and function of ERα through regulating the modification of ERα. Our study targets the role of UGT1A1 expression, glycosylation modification of ERα (estrogen receptor α) and estrogen resistance in development of TNBC

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call